SecBot SecBot
6-K ·Filed Nov 5, 2026

QGEN

QIAGEN N.V.
NEUTRAL
Impact 5/10
Horizonmonths Processed11d 7h ago SEC0001015820-26-000061
6-K: Earnings release
Actionable Insight • Neutral

The Q3 results modestly exceeded the company's own outlook, but the stock is now driven by the pending EQT take-private at $46.50/share, not quarterly operating performance. Monitor regulatory approvals and shareholder tender for deal completion timing, expected mid-2027.

DirectionNeutral
Confidencehigh
Horizonmonths

Price Chart

Loading chart...

Executive Summary

QIAGEN reported Q3 2026 net sales of $548M (+3% YoY, +3% CER) and adjusted diluted EPS of $0.65 ($0.65 CER), exceeding the outlook for ~1-2% CER growth and at least $0.62 CER. The company suspended its 2026 guidance due to the pending all-cash takeover by EQT Private Equity at $46.50 per share, with closing expected in mid-2027. GAAP diluted EPS declined 15% to $0.51 due to higher restructuring and acquisition-related charges.

Key Financial Metrics

EPS (Adj.)
$0.65
est $0.63 · +3.2% · GAAP: $0.51
Revenue
$548.0M
est $538.1M · +1.8% · +3.0% YoY
Rating
beat
Free Cash Flow
$318.5M
Gross Margin
64.6%

Key Facts

  • Q3 2026 net sales $548M, +3% YoY and +3% CER, above the outlook for ~1-2% CER growth
  • Adjusted diluted EPS $0.65 ($0.65 CER), above the outlook for at least $0.62 CER
  • GAAP diluted EPS $0.51, down 15% from $0.60 in Q3 2025
  • Adjusted operating income margin 30.4%, up 80 bps from 29.6%
  • Operating cash flow $447M for first nine months of 2026 vs $466M in prior-year period
  • Free cash flow $319M for nine months vs $336M in prior-year period
  • Suspended 2026 outlook due to pending EQT Private Equity acquisition at $46.50 per share
  • Leverage ratio increased to 1.0x from 0.7x at year-end 2025 after $500M synthetic share repurchase and $72M dividend payment
  • Parse Biosciences on track to exceed ~$40M sales target for 2026
  • QIAstat-Dx sales grew 11% CER; QuantiFERON sales flat at $136M

Financial Impact

Q3 net sales $548M, adjusted diluted EPS $0.65; guidance suspended due to pending take-private

revenueepsoperating margincash flow

Segment Breakdown

SegmentRevenueGrowth
Sample technologies$187.0M+10.0%
Diagnostic solutions$209.0M+1.0%
PCR Nucleic acid amplification$71.0M-5.0%
Genomics NGS$66.0M+9.0%
Other$14.0M-21.0%

Risk Factors

  • Pending EQT acquisition may not close as expected due to regulatory or shareholder hurdles
  • GAAP net income declined 19% YoY due to higher restructuring and acquisition costs
  • PCR nucleic acid amplification sales declined 5% CER, indicating weakness in a core product group
  • Free cash flow declined 5% for the nine-month period

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001015820-26-000061
Document: a2026q3prform6-k.htm0001015820-26-000061
Document: 0001015820-26-000061-index-headers.html0001015820-26-000061
Document: 0001015820-26-000061-index.html0001015820-26-000061
Document: 0001015820-26-000061.txt0001015820-26-000061
Earnings Context (Synthetic; results releases only)0001015820-26-000061

Track record

7 reports on QGEN

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +0.99% at T+5 after the Oct 27, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $50.33 to $49.89 Now $49.81 −1.03% ▼ −0.87% −3.47% vs SPY
  2. Nov 5, 202611d ago 6-K Bearish 6/10 Entry $50.33 to $49.89 Now $49.81 +1.03% ▲ +0.87% +3.47% vs SPY
  3. Nov 5, 202611d ago 6-K Neutral 5/10 Viewing No price data
  4. Nov 4, 202612d ago Institutional Cluster Mixed 3/10 Entry $50.86 to $50.10 Now $49.81 −2.06% ▼ −1.49% −4.78% vs SPY
  5. Oct 27, 202620d ago SC TO-C Bullish 7/10 Entry $50.33 to $50.83 Now $49.81 −1.03% ▲ +0.99% +1.71% vs SPY
  6. Oct 23, 202624d ago 6-K Bullish 8/10 Entry $50.39 to $50.22 Now $49.81 −1.15% ▼ −0.34% +0.22% vs SPY
  7. Oct 22, 202625d ago SC TO-C Bullish 8/10 Entry $50.22 to $50.34 Now $49.81 −0.82% ▲ +0.24% −0.47% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens in 8h 9m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026